Sionna Stock Falls 91% as Failed CF Trial Pushes Valuation Below Cash

Sionna Therapeutics closed 91.2% lower on Monday after its lead clinical readout failed. The company will not advance SION-719 as an add-on therapy in its current form.

11 August 2026

Sionna Therapeutics (NASDAQ:SION) Drops 92% After Failed Study, Shares Fall Below Gross Cash

WALTHAM, Massachusetts, August 10, 2026, 12:00 EDT — Sionna Therapeutics fell 92% after its study missed its main goal, sending the stock below the company's reported gross cash position.

10 August 2026

Biotechnology·NASDAQ:SION·Pharmaceuticals·Stock Market

Sionna Therapeutics (NASDAQ:SION) Drops 92% After Failed Study, Shares Fall Below Gross Cash

TechStock² Updates

DraftKings Faces $67.6 Million Loss on $13.1 Billion U.S. Open Betting Volume

Netflix Sets September 17 Return for Stranger Things: Tales From ’85, Eyes $3 Billion in Ad Revenue

Tesla Shares Drop 1.7% Amid $1.09 Trillion Market Cap and 1.4% Operating Margin

Micron Shares Edge Down 0.3% After $50 Billion Quarter Sets Higher Bar for September 30

Transocean Shares Gain 1.0% With $212 Million in Cash Flow Offset by $5.1 Billion Debt Burden

NuScale Power Drops 4.6% After Investors Weigh $4 Billion Valuation Against $75,000 Quarterly Revenue

Bank of America Shares Gain 1.9% as Rate Speculation Highlights $16 Billion Net Interest Income

Hyperliquid Strategies Stock Falls 9.5% as $2.4 Billion HYPE Treasury Tests Valuation

Moderna Shares Drop 3.4% with $55 Billion Valuation Raising Questions About Cancer Vaccine Progress

Ford Shares Edge Down 0.5% as $4 Billion EV Deficit Challenges $11 Billion Profit Target

Investment Disclaimer